SPECTROSCOPY
chromatography mass spectrometry (LC-MS) is most commonly used for dereplication in natural product drug discovery, as this combination is both sensitive and well suited for analysing complex mixtures. Te accurate mass of the compound can be used to calculate the elemental composition via high resolution MS, and then used to search databases such as MarinLit, Dictionary of Natural Products, and SciFinder, to identify unknown molecules.
ASSESSING BIOACTIVITY Te laboratory pre-fractionates the extracts into approximately eight fractions, which are tested for bioactivity, before using LC-MS to differentiate and select bioactive fractions from inactive fractions. However, any similar but non- identical compounds to those existing in the database will not be identified, so the laboratory uses ion mobility separation (IMS) quadrupole time-of-flight (QTof) MS to add information on MS/MS fragmentation in the dereplication process. Tese fragment data can be used to search MS fragment libraries, such as the Global Natural Products Social molecular networking (GNPS), to visualise specific fragmentation patterns that are similar, even though the accurate mass of the target molecule is difficult. Isolating the compound is the most time-consuming step of bioprospecting studies, and sometimes a compound is isolated that ultimately is a trivial metabolite that contributes no new information. Since IMS QTof MS technology was introduced to the Marbio laboratory, no trivial molecules have been isolated, and researchers can be more certain about the compounds they are working with.
CHARACTERISATION OF RHAMNOLIPIDS Recent work by the Marbio group shows the cultivation of a newly isolated arctic marine Pseudomonas sp. strain M10B774, which is affiliated with the P. fluorescence group. Fractions of the culture extracts were screened for antibacterial activity against the pathogenic bacteria Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, Escherichia coli, and Pseudomonas aeruginosa in a growth inhibition assay. Cytotoxic activity of the fractions was also evaluated against three cancer cell lines, human melanoma
Marbio scientists are focused on marine bioprospecting
(A2058), human breast carcinoma (MCF7), and human colon carcinoma (HT29), as well as the non-malignant normal lung fibroblast cell line (MRC5). Pseudomonas sp. was cultivated in four different media to activate biosynthetic pathways leading to the production of antibacterial and anticancer compounds, and culture extracts were pre-fractionated and screened for anticancer and antibacterial properties. Active fractions were dereplicated using molecular networking based on MS/MS fragmentation data, indicating the presence of a cluster of related rhamnolipids – compounds known to have antibacterial and cytotoxic activities. Six compounds were isolated using high performance liquid chromatography (HPLC) and mass-guided fractionation, and by interpreting the data from nuclear magnetic resonance (NMR) and high-resolution MS/MS analysis. Te project demonstrated the use of MS/MS-based molecular networking as a dereplication strategy to identify known compounds, their analogs and related compounds. For the first time, five mono- rhamnolipids from a bacterium within the P. fluorescence group were characterised, including one new mono-rhamnolipid, as well as the lipid moiety of one of the rhamnolipids. In addition, one fraction from three of the four growth conditions showed inhibitory activity towards bacteria and cancer cells. Instruments with high dynamic range
are vital to the work at Marbio laboratory, due to the variable concentrations of molecules within fractions and the sample complexity. Te sensitivity of IMS QTof MS is also required for users to distinguish between small and large peaks, to identify unknown molecules. Te high degree of
specificity provided by combining UPLC with IMS QTof MS also allows clearer and more comprehensive data and, when joined with modern software solutions for elucidation and database searching, researchers can mine more information to find new compounds faster. Such software platforms significantly reduce the data processing bottleneck by providing rapid access to results through efficient data acquisition and processing steps.
FUTURE DIRECTIONS Collaboration is vital for the Arctic University of Norway to progress newly discovered bioactive compounds through the pharmaceutical development pipeline to commercialisation. Te university’s industry partners, for example those at the Lead Discovery Center (LDC) at the Max Planck Institute for Medical Research, Germany, facilitate the development of a selection of the 30-50 compounds isolated by the Marbio laboratory per year. To continue discovering new drug candidates, the laboratory is continually improving its methods and workflows with newly emerging technology. Te natural products community is increasingly linking different types of data and conducting more work on metabolite profiles. Te university is also minimising its environmental impact by applying for funding to isolate compounds using supercritical fluid chromatography (SFC), which offers improved analytical scale and uses less organic solvents.
Dr Espen Hansen is a professor in marine biotechnology at Marbio
www.en.uit.no
www.scientistlive.com 41
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
